Celecoxib and colon cancer

New York, June 30, 2000 (Praxis Press) In familial adenomatous polyposis (FAP), a genetic disease that spurs the formation of hundreds of adenomatous polyps in the colon, the risk of developing colorectal cancer verges on 100 percent. Nonsteroidal antiinflammatory drugs (NSAIDs) are linked to a lower incidence of adenomatous polyps and lower colon cancer mortality, possibly due to their inhibition of the cyclooxygenase enzyme family, but their gastrointestinal toxicity limits their long-term use

June 30, 2000

New York, June 30, 2000 (Praxis Press) In familial adenomatous polyposis (FAP), a genetic disease that spurs the formation of hundreds of adenomatous polyps in the colon, the risk of developing colorectal cancer verges on 100 percent. Nonsteroidal antiinflammatory drugs (NSAIDs) are linked to a lower incidence of adenomatous polyps and lower colon cancer mortality, possibly due to their inhibition of the cyclooxygenase enzyme family, but their gastrointestinal toxicity limits their long-term use. In a recent study published in The New England Journal of Medicine, a six-month twice-daily treatment with 400 mg of celecoxib, a specific cyclooxygenase-2 inhibitor not associated with the gastric ulceration linked to traditional NSAIDs, significantly reduced the number of colorectal polyps in patients with FAP (see paper). After six months, patients had a 28 percent reduction in the mean number of colorectal polyps and a 30.7 percent reduction in the polyp burden. These findings suggest that celecoxib may become part of the pharmacologic strategy for the prevention of colorectal adenomas, once its long-term effects are evaluated.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech